About Sirna Therapeutics
Sirna Therapeutics is a company based in San Francisco (United States) founded in 1992 was acquired by Alnylam in January 2014. Sirna Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter San Francisco, United States
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sirna Therapeutics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sirna Therapeutics
Investors in Sirna Therapeutics
Sirna Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Credit Suisse and Oxford Bioscience Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage VC firm investing in the US and Korea
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Locked | Locked | Locked |
Investor details for Sirna Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sirna Therapeutics
Investment portfolio details for Sirna Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sirna Therapeutics
Detailed financials for Sirna Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sirna Therapeutics Comparisons
Peer comparison for Sirna Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sirna Therapeutics
Sirna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
Detailed competitors of Sirna Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sirna Therapeutics
Complete news archive for Sirna Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sirna Therapeutics
Sirna Therapeutics was founded in 1992 and raised its 1st funding round 11 years after it was founded.
Sirna Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sirna Therapeutics is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. The company develops small interfering RNA (siRNA) drugs. The company started a clinical trial of its siRNA-based treatment for age-related macular degeneration. The company went public in 2008. Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy. The company was acquired by Merck Co. in 2006 for 1.1B. In 2014, Sirna was acquired by Alnylam from Merck for 175M.
Sirna Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Sirna Therapeutics has 6 investors. Key investors include Alnylam, Credit Suisse, Oxford Bioscience Partners, Venrock, and GGV Capital.